Key Summary: On Feb 27, 2024, Ephraim Fields, Echo Lake Capital (9.3%), urged NeuroMetrix's Board to address its significant undervaluation. He advocates for immediate liquidation and seeks management's cooperation in announcing a liquidation plan to maximize shareholder value.Market Cap: $4 million | NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico.
On February 27, 2024, Ephraim Fields, Echo Lake Capital (9.3%) sent a letter to the Board stating that, "As of December 31, 2023, NeuroMetrix holds approximately $18.0 million in net cash, equating to about $12.00 per share, yet its stock trades at $3.50 per share, a 70% discount to its net cash value. This substantial undervaluation is attributed to perceived misalignment with shareholders' interests, evidenced by management's limited share ownership and questionable decisions, such as issuing shares at discounted prices and initiating a dual mandate strategic review." Echo Lake Capital urges immediate liquidation, citing the company's small size, uncertain growth prospects, excessive corporate overhead, and lack of shareholder confidence. They oppose a potential merger, advocating instead for full capital return to shareholders. Echo Lake Capital hopes for management's cooperation in announcing a liquidation plan to maximize shareholder value, expressing readiness for further action if necessary.
Comments